SCHEMBL25751771

SCHEMBL25751771

COC(=O)c1ccc(OC)c(-c2nc[nH]n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.50
KMT2A Q03164 5/20 0.46
MEN1 O00255 3/20 0.43
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
XDH P47989 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
TSHR P16473 2/20 0.41
CTSA P10619 1/20 0.41
GAA P10253 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GLA P06280 1/20 0.41
EGFR P00533 1/20 0.41
CYP2C9 P11712 2/20 0.40
LMNA P02545 2/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22288342 0.77 LRRK2 (0.44) MAPTKMT2AMEN1HSD17B10CYP2C9
SCHEMBL25751514 0.77 MAPT (0.50) MAPTKMT2AMEN1CA12CA1
SCHEMBL12127343 0.76 ALDH1A1 (0.50) KMT2AMEN1TSHRALDH1A1HSD17B10
SCHEMBL4554490 0.75 ALDH1A1 (0.55) MAPTKMT2AMEN1CA12CA1
SCHEMBL25751034 0.75 KMT2A (0.50) MAPTKMT2AMEN1CA12CA1
SCHEMBL13117486 0.73 HTT (0.49) MAPTKMT2ATSHRCTSAGAA
SCHEMBL35823 0.73 PTGS2 (0.58) MAPTKMT2AMEN1TSHRCTSA
SCHEMBL17559286 0.72 ABL1 (0.61) MAPTKMT2ACTSAEGFR
Veratric Acid Methyl Ester SCHEMBL29573244 0.72 MAPT (0.86) MAPTKMT2AMEN1CA12CA1
Veratric Acid Methyl Ester SCHEMBL2050732 0.72 MAPT (0.86) MAPTKMT2AMEN1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAPT 908/4885KMT2A 242/4885MEN1 2298/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 MAPT 908/4885KMT2A 242/4885MEN1 2298/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 MAPT 908/4885KMT2A 242/4885MEN1 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.